Aclarion (NASDAQ:ACON) Stock Price Down 5.3% – Should You Sell?

Aclarion, Inc. (NASDAQ:ACON) shares fell 5.3% on Monday . The company traded as low as $2.63 and last traded at $2.69. 61,034 shares changed hands during mid-day trading, a decline of 11% from the average daily volume of 68,744 shares. The stock had previously closed at $2.84.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Ascendiant Capital Markets raised their price target on shares of Aclarion from $7.00 to $7.50 and gave the stock a “buy” rating in a report on Friday, May 29th. Wall Street Zen raised shares of Aclarion from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Weiss Ratings upgraded shares of Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aclarion has a consensus rating of “Hold” and an average target price of $7.50.

Aclarion Stock Performance

The stock has a 50 day moving average price of $3.11 and a two-hundred day moving average price of $3.37. The company has a market capitalization of $6.54 million, a PE ratio of -0.29 and a beta of 1.21.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.55) by $0.21. Aclarion had a negative return on equity of 54.41% and a negative net margin of 10,320.51%.The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. Sell-side analysts predict that Aclarion, Inc. will post -4.51 earnings per share for the current year.

Aclarion announced that its board has initiated a share buyback plan on Wednesday, April 22nd that allows the company to repurchase $2.50 million in shares. This repurchase authorization allows the company to purchase up to 31% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.